Skip to main content

Table 4 Adverse events

From: Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study

Adverse events Grade 1-2 Grade 3-4
Alopecia 89.3% (25/28)  
Leucopenia 25.0% (7/28) 10.7% (3/28)
Fatigue 21.4% (6/28) 3.6% (1/28)
Anemia 21.4% (6/28)  
Nausea 21.4% (6/28) 3.6% (1/28)
Peripheral neuropathy 17.9% (5/28) 10.7% (3/28)
Transaminase increase 17.9% (5/28) 7.1% (2/28)
Anorexia 14.3% (4/28) 3.6% (1/28)
Diarrhea 14.3% (4/28) 3.6% (1/28)
Thrombocytopenia 14.3% (4/28)  
Hypothyroidism 14.3% (4/28) 3.6% (1/28)
Pneumonitis 10.7% (3/28) 3.6% (1/28)
Fever 10.7% (3/28)  
Abdominal pain 7.1% (2/28)  
Rash 3.6% (1/28)  
  1. Data are presented as percentages (number events/total). Adverse events were assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0)